What Questions Should You Ask Your Doctor About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Risk Assessment

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering whether these are signs of gastroparesis—a condition where stomach emptying is delayed. Decades of pharmacovigilance have established that tracking symptom onset and severity is essential for identifying potential drug-related adverse effects. This page outlines the symptoms to monitor and questions to raise with your healthcare provider.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among the most serious potential complications is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and bloating. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. In patients using Ozempic, these symptoms may be exacerbated or newly induced due to the drug's pharmacological effects. The pharmacology of Ozempic involves activation of GLP-1 receptors, which slows gastric motility and reduces postprandial glucose excursions. While this effect is intended for glycemic control, it can lead to significant gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Additional Gastrointestinal Effects

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's direct effect on gastric smooth muscle and the enteric nervous system. GLP-1 receptor agonists inhibit gastric emptying by relaxing the proximal stomach and contracting the pylorus, which can lead to delayed gastric emptying and symptoms of gastroparesis. This effect is dose-dependent and may persist even after dose stabilization, particularly in susceptible individuals. Additional gastrointestinal adverse reactions reported with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These findings underscore the potential for significant gastrointestinal morbidity.

Risk Considerations and Settlement-Related Factors

Risk considerations center on the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but does not specifically list gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of explicit mention of gastroparesis may leave patients and healthcare providers unaware of the potential for this serious complication. This gap in labeling could be relevant for settlement-related considerations, as affected patients may argue that the risks were not adequately communicated. Settlement-related considerations for patients who develop gastroparesis after using Ozempic involve several factors. First, the timeline between exposure and documented harm is critical. Gastrointestinal adverse reactions often occur during dose escalation, but symptoms of gastroparesis may develop gradually and persist even after discontinuation of the drug. Patients who experience severe or prolonged symptoms may require medical intervention, including hospitalization, nutritional support, and prokinetic agents. The economic burden includes medical costs, lost wages, and reduced quality of life. Legal claims may focus on whether the manufacturer provided sufficient warnings about the risk of gastroparesis and whether the drug's benefits outweigh its risks for individual patients. In summary, the evidence indicates that Ozempic is associated with a higher incidence of gastrointestinal adverse reactions compared to placebo, and these reactions can include symptoms consistent with gastroparesis. The mechanistic link through delayed gastric emptying is well-established. However, the prescribing information does not explicitly warn about gastroparesis, which may be a point of contention in settlement discussions. Patients who have experienced significant harm should consult with a qualified attorney to evaluate their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to symptoms of gastroparesis, such as nausea, vomiting, and abdominal pain. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a distinct adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of explicit warning may be relevant in legal claims.

What should I do if I developed gastroparesis after taking Ozempic?

If you have used Ozempic and developed gastroparesis, you should seek medical care for your symptoms and consult with a qualified attorney to evaluate your legal options, especially regarding potential settlements.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.